New Diet Pill Called Qnexa

Ukmedix has learnt of some of the clinical results of a new diet pill called Qnexa. The new drug Qxena is a combination of phentermine and another compound called topiramate which is presently licenced to treat the occurence of migraines seizures.

The results of the Phase II trial using 200 overweight participants have shown to be promising. The clinical trial was set up with a double blind and placebo format and lasted for nearly 6 months. Over 50% of the obese participants who were given the Qnexa drug saw a 10% and more weight loss over the course of the trial. Of the 200 participants, 159 were female and 41 were men. The average BMI was 38 and the average age was 40. The men and women were asked to eat 500 calories less each day. 

The researchers were also happy to note that when they looked at the weight loss data that the participants were continuing to lose weight at more or less the same rate meaning that tolerance to the drug was not happening and weakening its effects. Over ninety percent of the participants tolerated the drug well and continued using it till the end of the six month period.

The development of the drug Qnexa is helped by the fact that it is made up of 2 drugs that already have had FDA and EMEA approval, however the drug phentermine has a small cloud over it as it was a component of a drug called Fen-phen that had to be stopped on the market due to reports of heart valve injuries. For this reason it maybe some time before Qnexa starts to be sold as a diet drug.